Long non-coding RNAs as targets for immunosuppressive drug teriflunomide in anti-cancer potential for hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of molecular histology"
DOI: 10.1007/s10735-020-09912-6
Abstract: Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Because of the relatively chemotherapy-refractory nature of HCC and significant potential poor hepatic reserve, chemotherapy has not been used consistently in the treatment of… read more here.
Keywords: hepatocellular carcinoma; teriflunomide; ontology; drug ... See more keywords
Teriflunomide suppresses T helper cells and dendritic cells to alleviate experimental autoimmune uveitis.
Sign Up to like & getrecommendations! Published in 2019 at "Biochemical pharmacology"
DOI: 10.1016/j.bcp.2019.113645
Abstract: Autoimmune uveitis (AU), a sight-threatening intraocular disorder, is still a challenge for ophthalmologists in clinic. Teriflunomide has been approved for multiple sclerosis (MS) in 2012 for its immunoregulatory function. However, the effect and mechanisms of… read more here.
Keywords: teriflunomide; dendritic cells; autoimmune uveitis; uveitis ... See more keywords
Saliva as Blood Alternative in Therapeutic Monitoring of Teriflunomide—Development and Validation of the Novel Analytical Method
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23179544
Abstract: Therapeutic drug monitoring (TDM) is extremely helpful in individualizing dosage regimen of drugs with narrow therapeutic ranges. It may also be beneficial in the case of drugs characterized by serious side effects and marked interpatient… read more here.
Keywords: teriflunomide; concentration; monitoring; method ... See more keywords
Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study
Sign Up to like & getrecommendations! Published in 2018 at "Chinese Medical Journal"
DOI: 10.4103/0366-6999.246067
Abstract: Background: Disease-modifying therapy is the standard treatment for patients with multiple sclerosis (MS) in remission. The primary objective of the current analysis was to assess the efficacy and safety of two teriflunomide doses (7 mg… read more here.
Keywords: teriflunomide; teriflunomide group; analysis; group ... See more keywords